Policy & RegulationAnalysis
China Handled Over 14,000 Unfair Competition Cases in 2025, SAMR Reports
Regulators imposed 615 million yuan in penalties, zeroing in on digital commerce and pharmaceutical bribery.
Share
Photo by Déji Fadahunsi on Pexels
The Brief
Chinese market regulators investigated 14,679 unfair competition cases in 2025, imposing 615 million yuan in total fines and confiscations, according to an annual enforcement report released by the State Administration for Market Regulation. Unveiled at the 2026 National Fair Competition Conference, the report highlighted intensified scrutiny over online commerce, deceptive health product marketing targeting senior citizens via private livestreaming, and the rollout of new compliance guidelines against commercial bribery in the pharmaceutical industry.
Why it matters
Enforcement against unfair competition forms a core pillar of China's initiative to build a unified national market. The disclosed enforcement figures signal regulatory priorities, demonstrating that authorities are cracking down on predatory digital sales tactics and healthcare fraud while establishing clearer compliance boundaries for corporate marketing and competition.
China context
Chinese regulators have increasingly linked anti-monopoly and anti-unfair competition enforcement to curbing 'involution'—destructive, race-to-the-bottom price wars and deceptive marketing practices across saturated industries. Rather than relying solely on retrospective fines, market watchdogs are blending targeted enforcement campaigns with industry-specific compliance guidelines, such as rules addressing commercial bribery in healthcare, to clean up private-domain e-commerce and pharmaceutical distribution.
Editor's View
EDITOR'S VIEW — Analysis and inference, not factual reporting.
The 2025 figures underscore a pragmatic shift by market regulators toward consumer-facing digital abuses and healthcare practices. While total fines of 615 million yuan across nearly 15,000 cases point to relatively modest per-case penalties, the high volume of actions in online sectors and elderly-targeted marketing reflects a targeted effort to safeguard household welfare. Moreover, the formal focus on mitigating 'involution' demonstrates Beijing's intent to discourage destructive price and promotional wars without freezing genuine market dynamism.
What to watch
- Legislative and implementation milestones regarding the revised Anti-Unfair Competition Law.
- Follow-up enforcement actions and penalty cases in pharmaceutical marketing following the release of bribery prevention guidelines.
- Potential regulatory guidelines targeting cutthroat competition and aggressive pricing practices in other consumer sectors.
Key Takeaways
- 1Chinese authorities investigated 14,679 unfair competition cases in 2025, collecting 615 million yuan in fines and confiscations.
- 2Online enforcement remained a core focus, with 1,932 digital unfair competition cases penalized nationwide.
- 3Regulatory campaigns targeted false health claims and fraudulent private-domain livestreaming sales aimed at seniors.
- 4SAMR finalized revisions to the Anti-Unfair Competition Law and published anti-commercial bribery compliance guidelines for pharmaceutical firms.
Chinese market regulators investigated 14,679 cases of unfair competition in 2025, levying a combined 615 million yuan in fines and asset confiscations, according to the annual enforcement report released by the State Administration for Market Regulation (SAMR).
The bilingual Annual Report on China's Anti-Unfair Competition Law Enforcement (2025) was officially presented during a session on strengthening anti-unfair competition enforcement and enhancing governance against 'involution' at the 2026 National Fair Competition Conference, state media reported.
Digital markets accounted for a significant portion of regulatory activity. Nationwide, supervisory bodies penalized 1,932 cases involving online unfair competition during the year. Authorities launched dedicated campaigns targeting online malpractices, particularly deceptive promotional tactics in private livestream channels.
Regulators placed special emphasis on protecting vulnerable consumers, carrying out comprehensive enforcement campaigns against false and misleading advertising for pharmaceuticals and healthcare products directed at senior citizens. SAMR noted that these interventions effectively curbed abuses by private-domain livestream hosts that targeted elderly shoppers with exaggerated efficacy claims.
Beyond consumer digital commerce, the market regulator also moved to reinforce legal and sector-specific governance frameworks. According to report details cited by domestic media, SAMR completed revisions to the Anti-Unfair Competition Law and issued comprehensive compliance guidelines aimed at helping pharmaceutical enterprises identify and mitigate commercial bribery risks.
The enforcement drive reflects broader efforts by Chinese authorities to curb destructive price wars and fraudulent business models, aiming to build a fair, competitive marketplace and improve governance efficiency against market 'involution.'
Sources
- 《中国反不正当竞争执法年度报告（2025）》发布 — National Business Daily · 9/8/2026
- Com — People's Daily · 9/8/2026